FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Based on new data from two large clinical trials, FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your healthcare professional if you have questions or concerns. Do not stop taking your diabete...
Source: FDA Center for Drug Evaluation and Research - What's New - August 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Removes Boxed Warning About Risk of Leg and Foot Amputations for the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR)
August 26, 2020 - Based on a U.S. Food and Drug Administration (FDA) review of new data from three clinical trials, we have removed the Boxed Warning about amputation risk from the diabetes medicine canagliflozin (Invokana,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 26, 2020 Category: General Medicine Source Type: news
Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported
Canadian clinicians report the rare case of a 76-year-old woman who had a sharp spike in plasma levels of rosuvastatin within days of starting the SGLT2 inhibitor.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 5, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
In Rare Cases, Diabetes & Cholesterol Drug Combo Could Be Toxic
MONDAY, Aug. 3, 2020 -- Taking the statin Crestor in combination with the diabetes drug canagliflozin (Invokana) may have the potential to trigger statin toxicity, a new case report suggests.
Although this report details the problem in just one... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 3, 2020 Category: General Medicine Source Type: news
EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease
The CHMP has recommended approval for the SGLT2 inhibitor canagliflozin (Invokana) be extended to include diabetic kidney disease.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 1, 2020 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes
A subanalysis of CREDENCE suggests that SGLT2 inhibitor use should be based on clinical benefit, not solely glycemic control, say researchers. Another study hints that these drugs up EPO levels.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 10, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Highlights From ASN Kidney Week 2019 Highlights From ASN Kidney Week 2019
Highlights from ASN ' s Kidney Week 2019 include results from the CREDENCE trial showing benefit from the SGLT2 inhibitor canagliflozin for patients with established diabetic nephropathy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2019 Category: Consumer Health News Tags: Nephrology ReCAP Source Type: news
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA ® (canagliflozin) are Consistent Across Various Levels of Kidney Function
Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA ® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKDData announcemen t comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 12, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes and DKD
RARITAN, N.J., Sept. 30, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for Invokana (canagliflozin) to reduce the risk of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 30, 2019 Category: Drugs & Pharmacology Source Type: news
FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease
Results of CREDENCE lead to FDA approval for canagliflozin to slow kidney disease progression and reduce the risk of heart failure hospitalization in adults with type 2 diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 30, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
U.S. FDA Approves INVOKANA ® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
INVOKANA ® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKDApproval is based on the landmark Phase 3 CREDENCE renal outcomes study – the only completed renal out comes study of a diabetes medicine (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 30, 2019 Category: Pharmaceuticals Source Type: news
SUSTAIN-8: Semaglutide vs Canagliflozin After Metformin in T2D SUSTAIN-8: Semaglutide vs Canagliflozin After Metformin in T2D
Reduction in HbA1c and weight loss are superior with SC semaglutide compared with canagliflozin, but treatment decisions should also consider patient comorbidities, patient preference, tolerance, and cost.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 23, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
canagliflozin (Invokana)
Title: canagliflozin (Invokana)Category: MedicationsCreated: 4/10/2013 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 19, 2019 Category: Endocrinology Source Type: news
